Core Points - BioCardia, Inc. has regained compliance with Nasdaq Capital Market's Listing Requirements, confirming its ability to continue trading under the symbol "BCDA" [1][2] - The company has successfully improved its balance sheet by raising new capital to support the development of its therapeutic candidates and advance its approved products [1][2] Company Overview - BioCardia, Inc. is a leader in cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases [2] - The company has two main biotherapeutic platforms: CardiAMP autologous and CardiALLO™ allogeneic cell therapies, with three clinical stage product candidates currently in development [2] - BioCardia utilizes its Helix™ biotherapeutic delivery and Morph vascular navigation product platforms, and is set to introduce the Heart3D fusion imaging platform [2] - The company engages in selective partnerships for biotherapeutic delivery with peers developing significant biologic therapies [2]